Sanofi halts clinical programme of venglustat in autosomal dominant polycystic kidney disease

The STAGED-PKD study was stopped for futility after an independent analysis found venglustat, which inhibits the glycosphingolipid pathway, did not provide meaningful reduction in annualised rate change in total kidney volume compared to placebo.

Source:

PharmaTimes